In a randomized, double-blind, repeated crossover trial that involved almost 1,500 individuals with stage II hypertension, researchers found significant variation in individual responses to different antihypertensive treatments, particularly for lisinopril versus hydrochlorothiazide, lisinopril versus amlodipine, candesartan versus hydrochlorothiazide, and candesartan versus amlodipine. The study highlights the need for personalized antihypertensive therapy as there is substantial heterogeneity in blood pressure response to drug therapy for hypertension. The researchers recommend further studies to identify the mechanisms behind these individual differences to enable personalized antihypertensive therapy in routine clinical practice. This study’s findings underscore the importance of considering individualized treatment approaches for hypertension management to achieve optimal outcomes.